Prognostic Value of Complement Component 2 and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma

Table 5

Overlap of significant KEGG pathways enriched in HCC patients with higher C2 expression from the TCGA, GSE14520, and ICGC HCC cohorts.

ID	Description	TCGA cohort		GSE14520 cohort		ICGC cohort
		Count	.adjust	Count	.adjust	Count	.adjust
hsa04110	Cell cycle	96	0.000	33	0.003	89	0.000
hsa04610	Complement and coagulation cascades	59	0.000	42	0.000	64	0.000
hsa04152	AMPK signaling pathway	61	0.023	34	0.001	58	0.031
hsa03320	PPAR signaling pathway	42	0.014	27	0.000	40	0.025
hsa04910	Insulin signaling pathway	80	0.000	28	0.008	66	0.026
hsa01200	Carbon metabolism	73	0.000	44	0.000	71	0.000
hsa00630	Glyoxylate and dicarboxylate metabolism	20	0.012	13	0.002	21	0.004
hsa00620	Pyruvate metabolism	27	0.001	13	0.017	25	0.006
hsa01230	Biosynthesis of amino acids	42	0.011	33	0.000	48	0.000
hsa00410	Beta-alanine metabolism	19	0.039	11	0.021	19	0.030
hsa00270	Cysteine and methionine metabolism	29	0.017	16	0.008	29	0.012
hsa05110	Vibrio cholerae infection	31	0.006	17	0.004	35	0.000
hsa00010	Glycolysis/gluconeogenesis	42	0.001	22	0.002	36	0.029
hsa04979	Cholesterol metabolism	36	0.000	19	0.001	37	0.000
hsa00280	Valine, leucine, and isoleucine degradation	27	0.042	19	0.000	27	0.029
hsa00640	Propanoate metabolism	21	0.027	54	0.000	20	0.041
hsa00260	Glycine, serine, and threonine metabolism	23	0.048	16	0.001	26	0.004